Bioavailability of Ubiquinol in Huntington Disease



Status:Completed
Conditions:Neurology
Therapuetic Areas:Neurology
Healthy:No
Age Range:18 - Any
Updated:4/2/2016
Start Date:September 2009
End Date:May 2010
Contact:Lisa Deuel
Email:lisa.deuel@ctcc.rochester.edu
Phone:585-276-3987

Use our guide to learn which trials are right for you!

The death of brain cells in Huntington Disease (HD) is thought to be associated with a lack
of normal cell energy and harmful brain substances called free radicals. Coenzyme Q10 (CoQ)
is a marketed nutritional supplement that may prove useful in HD because it increases cell
energy and combats free radicals.

Most studies of CoQ have looked at only one formulation of CoQ ("ubiquinone") in HD. The
purpose of the study is to find out if people that switch from the common formulation of CoQ
("ubiquinone") to a different formulation ("ubiquinol") have higher levels of CoQ in their
blood after taking the same dose. The investigators also want to find out if this different
formulation is tolerable for individuals with HD.


Inclusion Criteria:

- Have manifest Huntington disease

- Be 18 years of age or older

- Be taking an oxidized formulation of CoQ for at least 30 days prior to the baseline
visit

- Be on a steady dose of all concomitant medications for at least 30 days prior to the
baseline visit

Exclusion Criteria:

- Have a history of intolerability of sensitivity to CoQ

- Have an unstable medical or psychiatric illness

- Be pregnant or breastfeeding; women of childbearing age must use reliable
contraception
We found this trial at
1
site
60 Crittenden Blvd # 70
Rochester, New York 14642
(585) 275-2121
University of Rochester The University of Rochester is one of the country's top-tier research universities....
?
mi
from
Rochester, NY
Click here to add this to my saved trials